[go: up one dir, main page]

EP2046782A4 - Derives imidazolylpyrimidine pour le traitement de maladies liees a la glycogene synthase kinase (gsk3) - Google Patents

Derives imidazolylpyrimidine pour le traitement de maladies liees a la glycogene synthase kinase (gsk3)

Info

Publication number
EP2046782A4
EP2046782A4 EP07748281A EP07748281A EP2046782A4 EP 2046782 A4 EP2046782 A4 EP 2046782A4 EP 07748281 A EP07748281 A EP 07748281A EP 07748281 A EP07748281 A EP 07748281A EP 2046782 A4 EP2046782 A4 EP 2046782A4
Authority
EP
European Patent Office
Prior art keywords
imidazolylpyrimidine
gsk3
derivatives
treatment
diseases related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07748281A
Other languages
German (de)
English (en)
Other versions
EP2046782A2 (fr
Inventor
Jeremy Burrows
Fernando Huerta
Fredrik Lake
Torben Pedersen
Tobias Rein
Didier Rotticci
Karin Staaf
Ulrika Yngve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2046782(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP2046782A2 publication Critical patent/EP2046782A2/fr
Publication of EP2046782A4 publication Critical patent/EP2046782A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07748281A 2006-06-27 2007-06-26 Derives imidazolylpyrimidine pour le traitement de maladies liees a la glycogene synthase kinase (gsk3) Withdrawn EP2046782A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81675606P 2006-06-27 2006-06-27
PCT/SE2007/000620 WO2008002244A2 (fr) 2006-06-27 2007-06-26 Nouveaux composés 384

Publications (2)

Publication Number Publication Date
EP2046782A2 EP2046782A2 (fr) 2009-04-15
EP2046782A4 true EP2046782A4 (fr) 2010-10-13

Family

ID=38846127

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07748281A Withdrawn EP2046782A4 (fr) 2006-06-27 2007-06-26 Derives imidazolylpyrimidine pour le traitement de maladies liees a la glycogene synthase kinase (gsk3)

Country Status (20)

Country Link
US (1) US20080188502A1 (fr)
EP (1) EP2046782A4 (fr)
JP (1) JP2009542638A (fr)
KR (1) KR20090024817A (fr)
CN (1) CN101511825A (fr)
AR (1) AR061652A1 (fr)
AU (1) AU2007265731A1 (fr)
BR (1) BRPI0713576A2 (fr)
CA (1) CA2655441A1 (fr)
CL (1) CL2007001881A1 (fr)
CO (1) CO6140059A2 (fr)
EC (1) ECSP088973A (fr)
IL (1) IL195666A0 (fr)
MX (1) MX2008015720A (fr)
NO (1) NO20090327L (fr)
RU (1) RU2008148902A (fr)
TW (1) TW200815418A (fr)
UY (1) UY30440A1 (fr)
WO (1) WO2008002244A2 (fr)
ZA (1) ZA200810484B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
JP4401428B2 (ja) 2006-06-27 2010-01-20 武田薬品工業株式会社 縮合環化合物
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
EP2419425A4 (fr) 2009-04-15 2012-08-29 Astrazeneca Ab Pyrimidines substituées par imidazole utiles dans le traitement de troubles liés à la glycogène synthase kinase 3, tels que la maladie d'alzheimer
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CN103724207B (zh) * 2013-12-20 2016-07-06 北京智博高科生物技术有限公司 苯基苄基醚类衍生物及其制备方法和应用
EP3741375A1 (fr) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement de maladies associées aux jonctions neuromusculaires
UY36547A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
WO2016207366A1 (fr) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement d'infections virales
TW201718514A (zh) 2015-08-07 2017-06-01 拜耳作物科學股份有限公司 作為殺蟲劑之經２－（雜）芳基取代之稠合雜環衍生物
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020512A1 (fr) * 2000-09-05 2002-03-14 Astrazeneca Ab Imidazolo-5-yl-2-anilino-pyrimidines utiles comme agents inhibiteurs de la proliferation cellulaire
WO2008002245A2 (fr) * 2006-06-27 2008-01-03 Astrazeneca Ab Nouveaux composés 385

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
JP2007500178A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
JP5164380B2 (ja) * 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
MX2007007272A (es) * 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
GB0504753D0 (en) * 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020512A1 (fr) * 2000-09-05 2002-03-14 Astrazeneca Ab Imidazolo-5-yl-2-anilino-pyrimidines utiles comme agents inhibiteurs de la proliferation cellulaire
WO2008002245A2 (fr) * 2006-06-27 2008-01-03 Astrazeneca Ab Nouveaux composés 385

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAEDA Y ET AL: "4-Acylamino -6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD- DOI:10.1016/J.BMCL.2004.05.064, vol. 14, no. 15, 2 August 2004 (2004-08-02), pages 3907 - 3911, XP008112654, ISSN: 0960-894X, [retrieved on 20040717] *

Also Published As

Publication number Publication date
MX2008015720A (es) 2008-12-19
AR061652A1 (es) 2008-09-10
WO2008002244A2 (fr) 2008-01-03
NO20090327L (no) 2009-02-09
IL195666A0 (en) 2009-09-01
WO2008002244A3 (fr) 2008-02-14
EP2046782A2 (fr) 2009-04-15
CA2655441A1 (fr) 2008-01-03
UY30440A1 (es) 2008-01-31
CL2007001881A1 (es) 2008-02-08
RU2008148902A (ru) 2010-08-10
KR20090024817A (ko) 2009-03-09
WO2008002244A8 (fr) 2008-10-09
ECSP088973A (es) 2009-01-30
US20080188502A1 (en) 2008-08-07
BRPI0713576A2 (pt) 2012-10-23
CO6140059A2 (es) 2010-03-19
ZA200810484B (en) 2009-08-26
JP2009542638A (ja) 2009-12-03
TW200815418A (en) 2008-04-01
CN101511825A (zh) 2009-08-19
AU2007265731A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
ZA200810577B (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (GSK3)
IL195666A0 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
EP2237664A4 (fr) Dérivés de (hét)aryl-p-quinone pour le traitement de maladies mitochondriales
PL2120932T3 (pl) Indazolowe pochodne jako inhibitory kinazy do leczenia raka
PL2349260T3 (pl) Inhibitory kinazy Janus do leczenia zespołu suchego oka i innych chorób związanych z okiem
ZA200810673B (en) 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
SI2125822T1 (sl) Substituirani pirazolo-kinazolinski derivati, postopek za njihovo pripravo in njihova uporaba kot inhibitorji kinaze
EP2063897A4 (fr) Inhibiteurs de kinases utiles pour le traitement de maladies prolifératives
EP2063896A4 (fr) Inhibiteurs de la kinase utiles dans le traitement de maladies prolifératives
IL195864A0 (en) 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
IL192880A0 (en) Therapeutic uses of inhibitors of rtp801
PT2097457T (pt) Derivados de polissacarídeos ácidos
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
ZA200904912B (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
IL196469A0 (en) New medical use of triazine derivatives
PT1847524E (pt) Derivados de terfenilo para o tratamento da doença de alzheimer
ZA200900230B (en) 4-hydroxythiobenzamide derivatives of drugs
ZA201008026B (en) Inhibitors of ikk-b serine-threonine protein kinase
GB0604899D0 (en) Derivatives of 18-glycyrrhetinic acid
IL212170A0 (en) Atropisomers of (hydroxyalkyl) pyrrole derivatives
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
HK1130784A (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
HK1130785A (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
EP2250178A4 (fr) Procédé amélioré destiné à la préparation de dérivés de triazol-benzodiazépine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130784

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20100910

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110409

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1130784

Country of ref document: HK